Zacks Investment Research cut shares of Obseva (NASDAQ:OBSV) from a buy rating to a hold rating in a research note issued to investors on Wednesday.

According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “

Several other research analysts have also issued reports on the stock. JPMorgan Chase & Co. started coverage on shares of Obseva in a research report on Thursday, September 13th. They issued an overweight rating and a $29.00 target price for the company. HC Wainwright set a $44.00 price target on shares of Obseva and gave the company a buy rating in a research report on Wednesday, August 29th. Leerink Swann began coverage on shares of Obseva in a research report on Wednesday, August 15th. They set an outperform rating and a $25.00 price target for the company. Wedbush set a $34.00 price target on shares of Obseva and gave the company a buy rating in a research report on Wednesday, October 3rd. Finally, BMO Capital Markets began coverage on shares of Obseva in a research report on Tuesday, June 12th. They set an outperform rating and a $23.00 price target for the company. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $28.00.

NASDAQ:OBSV traded up $0.30 during midday trading on Wednesday, hitting $16.30. The company had a trading volume of 45,087 shares, compared to its average volume of 83,021. Obseva has a 52-week low of $8.79 and a 52-week high of $20.35. The firm has a market capitalization of $656.95 million, a PE ratio of -7.24 and a beta of 1.49.

Obseva (NASDAQ:OBSV) last announced its earnings results on Wednesday, August 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.05. Equities analysts predict that Obseva will post -1.93 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in Obseva during the second quarter valued at about $349,000. Millennium Management LLC purchased a new stake in shares of Obseva during the second quarter worth about $2,459,000. Acuta Capital Partners LLC purchased a new stake in shares of Obseva during the second quarter worth about $6,424,000. Point72 Asset Management L.P. purchased a new stake in shares of Obseva during the second quarter worth about $3,028,000. Finally, DRW Securities LLC boosted its holdings in shares of Obseva by 55.0% during the second quarter. DRW Securities LLC now owns 33,812 shares of the company’s stock worth $512,000 after purchasing an additional 12,000 shares during the period. Institutional investors and hedge funds own 68.26% of the company’s stock.

About Obseva

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Featured Story: Treasury Bonds

Get a free copy of the Zacks research report on Obseva (OBSV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.